| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AACR Annual Meeting 2019
|
Collingridge, David
|
|
2019
|
20 |
5 |
p. 618
|
artikel
|
| 2 |
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
|
Fizazi, Karim
|
|
2019
|
20 |
5 |
p. 686-700
|
artikel
|
| 3 |
Adjuvant capecitabine in biliary tract cancer: a standard option?
|
Malka, David
|
|
2019
|
20 |
5 |
p. 606-608
|
artikel
|
| 4 |
Airbnb offers free accommodation for patients with cancer
|
Gourd, Elizabeth
|
|
2019
|
20 |
5 |
p. e251
|
artikel
|
| 5 |
Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study
|
Kickingereder, Philipp
|
|
2019
|
20 |
5 |
p. 728-740
|
artikel
|
| 6 |
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
|
Yang, James Chih-Hsin
|
|
2019
|
20 |
5 |
p. 602-603
|
artikel
|
| 7 |
Big data and machine learning algorithms for health-care delivery
|
Ngiam, Kee Yuan
|
|
2019
|
20 |
5 |
p. e262-e273
|
artikel
|
| 8 |
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|
Primrose, John N
|
|
2019
|
20 |
5 |
p. 663-673
|
artikel
|
| 9 |
Conclusions from quality of life studies in patients with resected high-risk melanoma: one part of the full story
|
Smithers, B Mark
|
|
2019
|
20 |
5 |
p. 611-612
|
artikel
|
| 10 |
Correction to Lancet Oncol 2019; 20: 420–35
|
|
|
2019
|
20 |
5 |
p. e242
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 719–27
|
|
|
2019
|
20 |
5 |
p. e243
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 335
|
|
|
2019
|
20 |
5 |
p. e242
|
artikel
|
| 13 |
Correction to Lancet Oncol 2019; 20: 636–48
|
|
|
2019
|
20 |
5 |
p. e242
|
artikel
|
| 14 |
Correction to Lancet Oncol 2019; 20: 674–85
|
|
|
2019
|
20 |
5 |
p. e242
|
artikel
|
| 15 |
Correction to Lancet Oncol 2019; 20: 663–73
|
|
|
2019
|
20 |
5 |
p. e242
|
artikel
|
| 16 |
Correction to Lancet Oncol 2017; 18: e143–52
|
|
|
2019
|
20 |
5 |
p. e242
|
artikel
|
| 17 |
Crowdfunding for cancer research: the TRACe campaign as an example
|
Gallerani, Giulia
|
|
2019
|
20 |
5 |
p. 622-624
|
artikel
|
| 18 |
Denosumab in early-stage breast cancer
|
Brandão, Mariana
|
|
2019
|
20 |
5 |
p. e234-e235
|
artikel
|
| 19 |
Denosumab in early-stage breast cancer
|
Rodriguez, Elena Gonzalez
|
|
2019
|
20 |
5 |
p. e233
|
artikel
|
| 20 |
Denosumab in early-stage breast cancer – Authors' reply
|
Gnant, Michael
|
|
2019
|
20 |
5 |
p. 236
|
artikel
|
| 21 |
Digital pathology and artificial intelligence
|
Niazi, Muhammad Khalid Khan
|
|
2019
|
20 |
5 |
p. e253-e261
|
artikel
|
| 22 |
Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective
|
Munshi, Anusheel
|
|
2019
|
20 |
5 |
p. e240
|
artikel
|
| 23 |
Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective – Authors' reply
|
Pramesh, C S
|
|
2019
|
20 |
5 |
p. e241
|
artikel
|
| 24 |
Early use of abiraterone and radium-223 in metastatic prostate cancer
|
Cursano, Maria Concetta
|
|
2019
|
20 |
5 |
p. e228
|
artikel
|
| 25 |
Early use of abiraterone and radium-223 in metastatic prostate cancer
|
Hindié, Elif
|
|
2019
|
20 |
5 |
p. e229
|
artikel
|
| 26 |
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|
Saito, Haruhiro
|
|
2019
|
20 |
5 |
p. 625-635
|
artikel
|
| 27 |
Ethical challenges of machine learning and deep learning algorithms
|
Prabhu, Sanjay P
|
|
2019
|
20 |
5 |
p. 621-622
|
artikel
|
| 28 |
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
|
Aderka, Dan
|
|
2019
|
20 |
5 |
p. e274-e283
|
artikel
|
| 29 |
Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
|
Marchetti, Claudia
|
|
2019
|
20 |
5 |
p. 603-605
|
artikel
|
| 30 |
First steps to regulate advertising of areca nut in China
|
Zhou, Bolun
|
|
2019
|
20 |
5 |
p. 615-616
|
artikel
|
| 31 |
Fulvestrant plus anastrozole for metastatic breast cancer
|
Burki, Talha Khan
|
|
2019
|
20 |
5 |
p. e247
|
artikel
|
| 32 |
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
|
Davies, Andrew
|
|
2019
|
20 |
5 |
p. 649-662
|
artikel
|
| 33 |
High-intensity end-of-life cancer care for young patients
|
Das, Manjulika
|
|
2019
|
20 |
5 |
p. e249
|
artikel
|
| 34 |
Importance of early treatment in metastatic prostate cancer: a question of life or death
|
Saad, Fred
|
|
2019
|
20 |
5 |
p. 609-611
|
artikel
|
| 35 |
Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge
|
Jardin, Fabrice
|
|
2019
|
20 |
5 |
p. 605-606
|
artikel
|
| 36 |
Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer
|
Konecny, Gottfried E
|
|
2019
|
20 |
5 |
p. 612-614
|
artikel
|
| 37 |
Inotuzumab ozogamicin in acute lymphoblastic leukaemia
|
Gourd, Elizabeth
|
|
2019
|
20 |
5 |
p. e248
|
artikel
|
| 38 |
Is it worth completely resecting hepatoblastoma at diagnosis?
|
Czauderna, Piotr
|
|
2019
|
20 |
5 |
p. 614-615
|
artikel
|
| 39 |
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
|
Makker, Vicky
|
|
2019
|
20 |
5 |
p. 711-718
|
artikel
|
| 40 |
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial
|
Katzenstein, Howard M
|
|
2019
|
20 |
5 |
p. 719-727
|
artikel
|
| 41 |
Moderately hypofractionated breast radiation therapy: is more evidence needed?
|
Marta, Gustavo Nader
|
|
2019
|
20 |
5 |
p. e226
|
artikel
|
| 42 |
Moderately hypofractionated breast radiation therapy: is more evidence needed? – Authors' reply
|
Wang, Shu-Lian
|
|
2019
|
20 |
5 |
p. e227
|
artikel
|
| 43 |
Nasal mucosal melanoma
|
Wahid, Nur Wahidah
|
|
2019
|
20 |
5 |
p. e284
|
artikel
|
| 44 |
NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
|
Elsada, Ahmed
|
|
2019
|
20 |
5 |
p. 619-620
|
artikel
|
| 45 |
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|
Moore, Kathleen N
|
|
2019
|
20 |
5 |
p. 636-648
|
artikel
|
| 46 |
Patient need, drug development, and risk
|
The Lancet Oncology,
|
|
2019
|
20 |
5 |
p. 601
|
artikel
|
| 47 |
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
|
Schadendorf, Dirk
|
|
2019
|
20 |
5 |
p. 701-710
|
artikel
|
| 48 |
Promising new combination therapy for non-GCB DLBCL
|
Gourd, Elizabeth
|
|
2019
|
20 |
5 |
p. e245
|
artikel
|
| 49 |
Regulating endocrine disruptors linked to cancer
|
Burki, Talha Khan
|
|
2019
|
20 |
5 |
p. e246
|
artikel
|
| 50 |
Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study
|
Mohamad, Osama
|
|
2019
|
20 |
5 |
p. 674-685
|
artikel
|
| 51 |
SABR versus conventional fractionation regimens in NSCLC
|
Addeo, Alfredo
|
|
2019
|
20 |
5 |
p. e230
|
artikel
|
| 52 |
SABR versus conventional fractionation regimens in NSCLC
|
Joseph, Nuradh
|
|
2019
|
20 |
5 |
p. e231
|
artikel
|
| 53 |
SABR versus conventional fractionation regimens in NSCLC – Authors' reply
|
Ball, David
|
|
2019
|
20 |
5 |
p. e232
|
artikel
|
| 54 |
Safety of complex cancer surgery across US hospitals
|
Das, Manjulika
|
|
2019
|
20 |
5 |
p. e252
|
artikel
|
| 55 |
Shortages of inexpensive essential medicines
|
Vyas, Malvika
|
|
2019
|
20 |
5 |
p. e224-e225
|
artikel
|
| 56 |
Should we expand the carbon ion footprint of prostate cancer?
|
Catton, Charles N
|
|
2019
|
20 |
5 |
p. 608-609
|
artikel
|
| 57 |
Supplemental ultrasonography for breast cancer screening
|
Das, Manjulika
|
|
2019
|
20 |
5 |
p. e244
|
artikel
|
| 58 |
Therapeutic HPV vaccine for cervical intraepithelial neoplasia
|
Burki, Talha Khan
|
|
2019
|
20 |
5 |
p. e250
|
artikel
|
| 59 |
Towards global elimination of cervical cancer in all groups of women
|
Kumar, Prabhat
|
|
2019
|
20 |
5 |
p. e237
|
artikel
|
| 60 |
Towards global elimination of cervical cancer in all groups of women
|
Whop, Lisa J
|
|
2019
|
20 |
5 |
p. e238
|
artikel
|
| 61 |
Towards global elimination of cervical cancer in all groups of women – Authors' reply
|
Simms, Kate T
|
|
2019
|
20 |
5 |
p. e239
|
artikel
|
| 62 |
Trump Administration stymies US EPA's chemical carcinogenicity and toxicity assessments
|
Furlow, Bryant
|
|
2019
|
20 |
5 |
p. 617
|
artikel
|
Tijdschrift beschrijving